Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | ADK | P55263 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21801390 | 1.00 | DGAT1 (0.32) | DGAT1ADK | |
| SCHEMBL21678406 | 0.85 | DGAT1 (0.33) | DGAT1ADK | |
| SCHEMBL21678412 | 0.85 | DGAT1 (0.32) | DGAT1ADK | |
| SCHEMBL21678534 | 0.82 | MAP3K7 (0.35) | DGAT1ADK | |
| SCHEMBL21701295 | 0.80 | MAP3K7 (0.37) | DGAT1ADK | |
| SCHEMBL16259168 | 0.80 | ADK (0.40) | DGAT1ADK | |
| SCHEMBL31340598 | 0.80 | ADK (0.40) | DGAT1ADK | |
| SCHEMBL25282686 | 0.79 | ADK (0.42) | DGAT1ADK | |
| SCHEMBL16785958 | 0.79 | DGAT1 (0.36) | DGAT1ADK | |
| SCHEMBL1706679 | 0.79 | ADK (0.42) | DGAT1ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964988-B2 | Fused heterocyclic compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-3849986-B1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-14 | — | — | US | disclosed |
| EP-3849986-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020055672-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, FRK | DGAT1 4768/4885ADK 841/4885 |
| US-11964988-B2 | Fused heterocyclic compounds as RET kinase inhibitors | RET, ROR1, FRK | DGAT1 4768/4885ADK 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.